P3-019: THE EFFECTS OF DIET INTERVENTION ON METABOLIC HEALTH AND CEREBRAL SPINAL FLUID ALZHEIMER'S DISEASE BIOMARKERS: A RANDOMIZED TRIAL

2006 ◽  
Vol 14 (7S_Part_19) ◽  
pp. P1069-P1070
Author(s):  
Ashley H. Sanderlin ◽  
Siobhan M. Hoscheidt ◽  
Angela J. Hanson ◽  
Laura D. Baker ◽  
Kaycee M. Sink ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Randomized Trial ◽  
Cerebral Spinal Fluid ◽  
Metabolic Health ◽  
Spinal Fluid ◽  
Disease Biomarkers ◽  
Diet Intervention

scholarly journals Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid‐life: A randomized trial

2021 ◽  
Author(s):  
Siobhan Hoscheidt ◽  
Ashley H. Sanderlin ◽  
Laura D. Baker ◽  
Youngkyoo Jung ◽  
Samuel Lockhart ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Randomized Trial ◽  
Cerebral Perfusion ◽  
Western Diet ◽  
Disease Biomarkers

scholarly journals From The Cover: Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease

2005 ◽  
Vol 102 (7) ◽  
pp. 2273-2276 ◽  
Author(s):  
D. G. Georganopoulou ◽  
L. Chang ◽  
J.-M. Nam ◽  
C. S. Thaxton ◽  
E. J. Mufson ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebral Spinal Fluid ◽  
Spinal Fluid

Nanoparticle-Based Detection in Cerebral Spinal Fluid of a Soluble Pathogenic Biomarker for Alzheimer’s Disease*

2020 ◽  
pp. 1509-1521
Author(s):  
Dimitra G. Georganopoulou ◽  
Lei Chang ◽  
Jwa-Min Nam ◽  
C. Shad Thaxton ◽  
Elliott J. Mufson ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebral Spinal Fluid ◽  
Spinal Fluid

scholarly journals Cerebral spinal fluid biomarker profiles in CNS infection associated with HSV and VZV mimic patterns in Alzheimer’s disease

2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Makiko Shinomoto ◽  
Takashi Kasai ◽  
Harutsugu Tatebe ◽  
Fukiko Kitani-Morii ◽  
Takuma Ohmichi ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebral Spinal Fluid ◽  
Spinal Fluid ◽  
Cns Infection ◽  
Fluid Biomarker

scholarly journals Visit-to-visit Blood Pressure Variability and Regional Cerebral Perfusion Decline in Older Adults

2020 ◽  
Author(s):  
Isabel Sible ◽  
Belinda Yew ◽  
Shubir Dutt ◽  
Katherine J. Bangen ◽  
Yanrong Li ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Blood Pressure ◽  
Older Adults ◽  
Alzheimer's Disease ◽  
Amyloid Beta ◽  
Blood Pressure Variability ◽  
Cerebral Perfusion ◽  
Cerebral Spinal Fluid ◽  
Spinal Fluid ◽  
Phosphorylated Tau

Abstract Background: Blood pressure variability has been linked to dementia risk, independent of average blood pressure levels. It has been hypothesized that dysregulated blood pressure may challenge autoregulatory mechanisms and risk cerebral hypoperfusion. The current study examined whether visit-to-visit blood pressure variability over one year is related to concurrent regional cerebral perfusion decline over the same period in older adults.Methods: Sixty-three older adults without history of dementia or stroke underwent repeated blood pressure measurement and arterial spin-labelling magnetic resonance imaging over the same one year period. Fluorodeoxyglucose-positron emission tomography determined cerebral metabolism at baseline. A subset underwent lumbar puncture to detect cerebral spinal fluid amyloid-beta (n=18) and phosphorylated tau (n=21) abnormalities. Visit-to-visit blood pressure variability and change in regional cerebral perfusion were both calculated over 12 months. Multiple linear regression examined relationships between blood pressure variability and change in regional perfusion after controlling for age, sex, average blood pressure, antihypertensive medication use and cerebral metabolism. Exploratory analyses were repeated in participant subsets with abnormal cerebral spinal fluid amyloid-beta and phosphorylated tau.Results: Elevated blood pressure variability was related to perfusion decline in medial orbitofrontal cortex (ß = -.36; p = .008), hippocampus (ß = -.37; p = .005), entorhinal cortex (ß = -.48; p < .001), precuneus (ß = -.31; p = .02), inferior parietal cortex (ß = -.44; p < .001) and inferior temporal cortex (ß = -.46; p < .001). Elevated blood pressure variability was similarly related to perfusion decline in some regions among participant subsets showing abnormal cerebral spinal fluid amyloid-beta and phosphorylated tau.Conclusions: Older adults with elevated visit-to-visit blood pressure variability exhibit concurrent regional cerebral perfusion decline in areas vulnerable to cerebrovascular dysfunction in Alzheimer’s disease, independent of cerebral hypometabolism. Similar findings are observed in exploratory analyses of older adults with Alzheimer’s disease biomarker abnormalities. The study is limited by the small sample size, particularly the subset of participants with Alzheimer’s disease biomarker abnormalities. Findings may have therapeutic implications, given that certain antihypertensive medications have differential effects on variability of blood pressure independent of average levels.

scholarly journals A blood-based signature of cerebral spinal fluid Aβ1–42 status

2017 ◽  
Author(s):  
Benjamin Goudey ◽  
Bowen J Fung ◽  
Christine Schieber ◽  
Noel G Faux ◽  
◽  
...  
Keyword(s):  
Machine Learning ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Minimally Invasive ◽  
Cerebral Spinal Fluid ◽  
Spinal Fluid ◽  
Carrier Status ◽  
Learning Approach ◽  
Risk Indicator ◽  
Machine Learning Approach

ABSTRACTIt is increasingly recognized that Alzheimer’s disease (AD) exists before dementia is present and that shifts in amyloid beta occur long before clinical symptoms can be detected. Early detection of these molecular changes is a key aspect for the success of interventions aimed at slowing down rates of cognitive decline. Recent evidence indicates that of the two established methods for measuring amyloid, a decrease in cerebral spinal fluid (CSF) amyloid β1−42 (Aβ1−42) may be an earlier indicator of Alzheimer’s disease risk than measures of amyloid obtained from Positron Emission Topography (PET). However, CSF collection is highly invasive and expensive. In contrast, blood collection is routinely performed, minimally invasive and cheap. In this work, we develop a blood-based signature that can provide a cheap and minimally invasive estimation of an individual’s CSF amyloid status using a machine learning approach. We show that a Random Forest model derived from plasma analytes can accurately predict subjects as having abnormal (low) CSF Aβ1−42 levels indicative of AD risk (0.84 AUC, 0.78 sensitivity, and 0.73 specificity). Refinement of the modeling indicates that only APOEε4 carrier status and four analytes are required to achieve a high level of accuracy. Furthermore, we show across an independent validation cohort that individuals with predicted abnormal CSF Aβ1−42 levels transitioned to an AD diagnosis over 120 months significantly faster than those predicted with normal CSF Aβ1−42 levels and that the resulting model also performs reasonably across PET Aβ1−42 status.This is the first study to show that a machine learning approach, using plasma protein levels, age and APOEε4 carrier status, is able to predict CSF Aβ1-42 status, the earliest risk indicator for AD, with high accuracy.

Nanoparticle-Based Detection in Cerebral Spinal Fluid of a Soluble Pathogenic Biomarker for Alzheimer’s Disease*

2020 ◽  
pp. 1509-1521
Author(s):  
Dimitra G. Georganopoulou ◽  
Lei Chang ◽  
Jwa-Min Nam ◽  
C. Shad Thaxton ◽  
Elliott J. Mufson ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebral Spinal Fluid ◽  
Spinal Fluid

Nanoparticle-Based Detection in Cerebral Spinal Fluid of a Soluble Pathogenic Biomarker for Alzheimer’s Disease*

2020 ◽  
pp. 1509-1521
Author(s):  
Dimitra G. Georganopoulou ◽  
Lei Chang ◽  
Jwa-Min Nam ◽  
C. Shad Thaxton ◽  
Elliott J. Mufson ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebral Spinal Fluid ◽  
Spinal Fluid

scholarly journals Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer’s Disease

2021 ◽  
pp. 1-9
Author(s):  
D. Kellar ◽  
S.N. Lockhart ◽  
P. Aisen ◽  
R. Raman ◽  
R.A. Rissman ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
White Matter ◽  
Cerebral Spinal Fluid ◽  
Spinal Fluid ◽  
White Matter Hyperintensity ◽  
Intranasal Insulin ◽  
Fluid Biomarker

Background: Intranasally administered insulin has shown promise in both rodent and human studies in Alzheimer’s disease; however, both effects and mechanisms require elucidation. Objective: We assessed the effects of intranasally administered insulin on white matter health and its association with cognition and cerebral spinal fluid biomarker profiles in adults with mild cognitive impairment or Alzheimer’s disease in secondary analyses from a prior phase 2 clinical trial (NCT01767909). Design: A randomized (1:1) double-blind clinical trial. Setting: Twelve sites across the United States. Participants: Adults with mild cognitive impairment or Alzheimer’s disease. Intervention: Participants received either twice daily placebo or insulin (20 IU Humulin R U-100 b.i.d.) intranasally for 12 months. Seventy-eight participants were screened, of whom 49 (32 men) were enrolled. Measurements: Changes from baseline in global and regional white matter hyperintensity volume and gray matter volume were analyzed and related to changes in cerebral spinal fluid biomarkers, Alzheimer’s Disease Assessment Scale-Cognition, Clinical Disease Rating-Sum of Boxes, Alzheimer’s Disease Cooperative Study–Activities of Daily Living Scale, and a memory composite. Results: The insulin-treated group demonstrated significantly reduced changes in white matter hyperintensity volume in deep and frontal regions after 12 months, with a similar trend for global volume. White matter hyperintensity volume progression correlated with worsened Alzheimer’s disease cerebral spinal fluid biomarker profile and cognitive function; however, patterns of correlations differed by treatment group. Conclusion: Intranasal insulin treatment for 12 months reduced white matter hyperintensity volume progression and supports insulin’s potential as a therapeutic option for Alzheimer’s disease.

Sign in / Sign up

Export Citation Format

Share Document